The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Recommendations for selecting and sequencing JAK inhibitors for patients with myelofibrosis
Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, shares his recommendations for selecting and sequencing JAK inhibitors in myelofibrosis (MF). Prof. Oh explains that a combination of several important patient-specific factors must be considered and highlights examples for the appropriate use of ruxolitinib, momelotinib, and pacritinib. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
